益生菌补充剂减轻乳腺癌患者化疗相关认知障碍:一项随机、双盲、安慰剂对照试验
该随机、双盲、安慰剂对照试验纳入159例需辅助化疗的I-III期乳腺癌患者,2018至2019年间随机接受益生菌或安慰剂(每次三粒、每日两次)干预,评估认知、焦虑抑郁及血浆标志物、代谢物和粪便微生物组成。结果显示益生菌补充显著降低化疗相关认知障碍(CRCI)发生率、改善整体认知功能、改变肠道微生物组成并调节九种血浆代谢物变化,其中p-Mentha-1,8-dien-7-ol、Linoelaidyl carnitine和1-aminocyclopropane-1-carboxylic acid与CRCI发生呈负相关;大鼠实验进一步显示外源性p-Mentha-1,8-dien-7-ol可减轻化疗诱导的海马长时程增强损害、突触损伤、氧化应激和胶质激活。
要点
- 益生菌补充显著降低乳腺癌患者化疗相关认知障碍发生率并改善整体认知功能。
- 益生菌改变肠道微生物组成并调节九种血浆代谢物变化。
- p-Mentha-1,8-dien-7-ol等三种代谢物与CRCI发生呈负相关。
核心结论
- 益生菌补充通过调节包括p-Mentha-1,8-dien-7-ol在内的血浆代谢物,预防乳腺癌患者CRCI的发生。
研究设计与样本
- 随机、双盲、安慰剂对照试验(ChiCTR-INQ-17014181),纳入159例I-III期需辅助化疗的乳腺癌患者。
- 2018至2019年筛选、入组并随机分配接受益生菌或安慰剂(每次三粒、每日两次)化疗期间干预。
- 评估认知、焦虑和抑郁,检测血浆生物标志物、代谢物和粪便微生物组成。
- 在大鼠中评估临床试验发现的代谢物对长时程增强、突触损伤、氧化应激和胶质激活的全身效应。
主要发现
- 益生菌补充显著降低CRCI发生率、改善整体认知功能、改变肠道微生物组成并调节九种血浆代谢物变化。
- p-Mentha-1,8-dien-7-ol、Linoelaidyl carnitine和1-aminocyclopropane-1-carboxylic acid与CRCI发生呈负相关。
- 益生菌补充增加大鼠血浆p-Mentha-1,8-dien-7-ol。
- 外源性p-Mentha-1,8-dien-7-ol给药显著减轻化疗诱导的大鼠海马长时程增强损害、突触损伤、氧化应激和胶质激活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemotherapy-related cognitive impairment (CRCI) is highly prevalent in patients with cancer and is associated with poor outcomes and quality of life. To date, the management of CRCI remains a clinical challenge. Herein, we aim to determine the preventive effects of probiotics on CRCI development and underlying mechanisms. METHODS: We conducted a randomised, double-blind and placebo-controlled trial (ChiCTR-INQ-17014181) of 159 patients with breast cancer and further investigated the underlying mechanism in a pre-clinical setting. From 2018 to 2019, patients with breast cancer (Stage I-III) who needed adjuvant chemotherapy were screened, enrolled and randomly assigned to receive either probiotics or placebo (three capsules, twice/day) during chemotherapy. Their cognition, anxiety and depression were assessed with well-established assays; their plasma biomarkers, metabolites and faecal microbiota compositions were measured. In addition, the systemic effects of the metabolites found in the clinical trial on long-term potentiation, synapse injury, oxidative stress and glial activation were assessed in rats. RESULTS: Probiotics supplement significantly decreased the incidence of CRCI, improved the allover cognitive functions, changed the gut microbial composition and modulated nine plasma metabolite changes. Among these metabolites, p-Mentha-1,8-dien-7-ol, Linoelaidyl carnitine and 1-aminocyclopropane-1-carboxylic acid were negatively correlated with the occurrence of CRCI. Furthermore, probiotics supplement increased plasma p-Mentha-1,8-dien-7-ol in rats. Administration of exogenous p-Mentha-1,8-dien-7-ol significantly alleviated chemotherapy-induced long-term potentiation impairment, synapse injury, oxidative stress and glial activation in the hippocampus of rats. CONCLUSION: Our data indicated that probiotics supplement prevents the occurrence of CRCI in patients with breast cancer via modulating plasma metabolites, including p-Mentha-1,8-dien-7-ol. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR-INQ-17014181) [http://www.chictr.org.cn/showproj.aspx?proj=24294].
引用
- Juan Z, Chen J, Ding B, et al. Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial. Eur J Cancer. 2021. PMID: 34896904. doi:10.1016/j.ejca.2021.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。